BridgeBio Oncology Therapeutics has announced a merger with Helix Acquisition Corp. II, a special purpose acquisition company (SPAC), which is set to raise over $450 million. This significant funding will bolster the company’s efforts to advance clinical testing for three innovative drug candidates targeting a previously elusive group of cancer targets. Set to be listed…

On a tumultuous Monday night, President Trump wielded the pen of executive authority to sign a slew of orders that have ignited controversy and raised questions about their legality. Among these was a significant halt to the enforcement of the Protecting Americans from Foreign Adversary Controlled Applications Act (PAFACA), commonly known as the TikTok ban….

Last year proved to be a pivotal period for the healthcare sector, marked by notable shifts in merger and acquisition (M&A) activity, as outlined in a recent report by Kaufman Hall. The findings indicate an ongoing, albeit unsteady, financial recovery for hospitals across the nation, punctuated by a surge in M&A deals — specifically, those…

In a presentation at the annual J.P. Morgan Healthcare Conference, Galapagos CEO Paul Stoffels illuminated the necessary evolution not only of his company but also of Gilead. As patient needs and therapeutic technologies have changed, both companies have reassessed their roles in the market. Galapagos is now leaving behind its initial concentration on small molecules…

In recent political developments, Congress finds itself in a precarious position as the specter of a TikTok ban looms large. What began as a bold stand against a controversial social media platform has spiraled into a chaotic scramble, with lawmakers grappling to find an American buyer in the wake of mounting pressures. Senator Chuck Schumer…